AbbVie and Neomorph Announce Collaboration to Develop …
4 days ago · "Protein degraders represent a groundbreaking advancement in the field of drug discovery and at AbbVie we are committed to advancing this technology forward," said Steven Elmore, vice president, small molecule therapeutics and platform technologies at AbbVie. "We are excited to collaborate with Neomorph to develop novel molecular glue degraders ...
AbbVie Completes Acquisition of Nimble Therapeutics
4 days ago · For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube. Forward-Looking Statements . Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995.
AbbVie Completes Acquisition of Nimble Therapeutics - PR …
3 days ago · News provided by AbbVie Jan 23, 2025, 09:16 ET. Share this article. Share to X. Share this article. Share to X. Acquisition adds potential novel oral peptide IL23R inhibitor for psoriasis as well ...
AbbVie News Center - News
3 days ago · AbbVie (NYSE: ABBV) will present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. Management will participate in a fireside chat at 10:15 a.m. Central time. A... Looking for more news from AbbVie? Follow us on social media.
AbbVie and Neomorph Announce Collaboration to Develop …
3 days ago · News provided by AbbVie Jan 23, 2025, 09:00 ET. Share this article. Share to X. Share this article. Share to X. Collaboration leverages AbbVie's expertise in oncology and immunology drug ...
AbbVie raises 2024 profit forecast on strong sales of key drugs …
Oct 30, 2024 · AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter earnings, sending ...
AbbVie Provides Update on Phase 2 Results for Emraclidine in …
Nov 11, 2024 · AbbVie (NYSE: ABBV) today announced that its two Phase 2 EMPOWER trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia who are experiencing an...
AbbVie lifts 2024 profit forecast, shares hit record high
Jul 25, 2024 · AbbVie increased its profit forecast for 2024 on Thursday after reporting strong sales of immunology drugs and quarterly results that exceeded Wall Street expectations, sending its shares to a...
AbbVie raises 2024 profit forecast on strong sales of key drugs …
Oct 30, 2024 · (Reuters) -AbbVie raised its annual profit forecast after strong sales of its newer immunology drugs and key cancer treatment helped the company beat Wall Street estimates for third-quarter...
AbbVie banks on Alzheimer's therapy with $1.4 billion buy of Aliada
Oct 28, 2024 · AbbVie is expanding its neuroscience portfolio as it faces a 33% drop in sales of its blockbuster arthritis drug Humira.